AR018187A1 - Derivados de 1,4-dihidro-1,3-diazinas y 3,4-dihidro-1,3-diazinas, procedimiento para su preparacion, medicamentos, procedimiento para la produccion de los mismos y el uso de los mismos para la produccion de medicamentos - Google Patents

Derivados de 1,4-dihidro-1,3-diazinas y 3,4-dihidro-1,3-diazinas, procedimiento para su preparacion, medicamentos, procedimiento para la produccion de los mismos y el uso de los mismos para la produccion de medicamentos

Info

Publication number
AR018187A1
AR018187A1 ARP990101779A ARP990101779A AR018187A1 AR 018187 A1 AR018187 A1 AR 018187A1 AR P990101779 A ARP990101779 A AR P990101779A AR P990101779 A ARP990101779 A AR P990101779A AR 018187 A1 AR018187 A1 AR 018187A1
Authority
AR
Argentina
Prior art keywords
substituted
hydroxy
phenyl
same
halogen
Prior art date
Application number
ARP990101779A
Other languages
English (en)
Spanish (es)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AR018187A1 publication Critical patent/AR018187A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
ARP990101779A 1998-04-18 1999-04-16 Derivados de 1,4-dihidro-1,3-diazinas y 3,4-dihidro-1,3-diazinas, procedimiento para su preparacion, medicamentos, procedimiento para la produccion de los mismos y el uso de los mismos para la produccion de medicamentos AR018187A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19817264A DE19817264A1 (de) 1998-04-18 1998-04-18 Neue Dihydropyrimidine

Publications (1)

Publication Number Publication Date
AR018187A1 true AR018187A1 (es) 2001-10-31

Family

ID=7864972

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101779A AR018187A1 (es) 1998-04-18 1999-04-16 Derivados de 1,4-dihidro-1,3-diazinas y 3,4-dihidro-1,3-diazinas, procedimiento para su preparacion, medicamentos, procedimiento para la produccion de los mismos y el uso de los mismos para la produccion de medicamentos

Country Status (36)

Country Link
US (3) US6696451B1 (enExample)
EP (1) EP1080086B1 (enExample)
JP (2) JP4590097B2 (enExample)
KR (1) KR100636771B1 (enExample)
CN (1) CN1159311C (enExample)
AR (1) AR018187A1 (enExample)
AT (1) ATE223401T1 (enExample)
AU (1) AU740318B2 (enExample)
BG (1) BG64649B1 (enExample)
BR (2) BRPI9917862B8 (enExample)
CA (1) CA2328780C (enExample)
CO (1) CO5021127A1 (enExample)
CU (1) CU23049A3 (enExample)
CZ (1) CZ293482B6 (enExample)
DE (2) DE19817264A1 (enExample)
DK (1) DK1080086T3 (enExample)
ES (1) ES2183548T3 (enExample)
GT (1) GT199900056A (enExample)
HU (1) HUP0102372A3 (enExample)
ID (1) ID27263A (enExample)
IL (2) IL138584A0 (enExample)
MY (1) MY126527A (enExample)
NO (2) NO321985B1 (enExample)
NZ (1) NZ507569A (enExample)
PE (1) PE20000427A1 (enExample)
PL (1) PL193898B1 (enExample)
PT (1) PT1080086E (enExample)
RU (1) RU2245881C9 (enExample)
SI (1) SI1080086T1 (enExample)
SK (1) SK286407B6 (enExample)
SV (1) SV1999000047A (enExample)
TR (1) TR200003011T2 (enExample)
TW (1) TW548274B (enExample)
UA (1) UA63998C2 (enExample)
WO (1) WO1999054326A1 (enExample)
ZA (1) ZA200005136B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4289100A (en) * 1999-03-25 2000-10-16 Bayer Aktiengesellschaft Dihydropyrimidines and their use in the treatment of hepatitis
AU5568400A (en) 1999-06-23 2001-01-09 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
WO2001045712A1 (de) * 1999-12-22 2001-06-28 Bayer Aktiengesellschaft Arzneimittelkombinationen gegen virale erkrankungen
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013125A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10125131A1 (de) 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
US20040092735A1 (en) * 2002-11-08 2004-05-13 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of cefuroxime sodium
CN101104604B (zh) * 2006-07-10 2011-03-02 挗äșŹæ‘©ćŠ›ć…‹ç§‘æŠ€æœ‰é™ć…Źćž 慉歩çșŻäșŒæ°ąć˜§ć•¶ç±»ćŒ–ćˆç‰©ćŠć…¶ç”šäșŽćˆ¶ć€‡æČ»ç–—ć’Œéą„é˜Čç—…æŻ’æ€§ç–Ÿç—…çš„èŻç‰©çš„ç”šé€”
CN101104617B (zh) 2006-07-10 2010-06-23 挗äșŹæ‘©ćŠ›ć…‹ç§‘æŠ€æœ‰é™ć…Źćž äșŒæ°ąć˜§ć•¶ç±»ćŒ–ćˆç‰©ćŠć…¶ç”šäșŽćˆ¶ć€‡æČ»ç–—ć’Œéą„é˜Čç—…æŻ’æ€§ç–Ÿç—…çš„èŻç‰©çš„ç”šé€”
RU2452733C2 (ru) * 2007-04-27 2012-06-10 ПэЮью Đ€Đ°Ń€ĐŒĐ° Л.П. ĐĐœŃ‚Đ°ĐłĐŸĐœĐžŃŃ‚Ń‹ trpv1 Đž ох ĐżŃ€ĐžĐŒĐ”ĐœĐ”ĐœĐžĐ”
AU2008265397C1 (en) 2007-06-18 2013-08-29 Sunshine Lake Pharma Co., Ltd. Bromo-phenyl substituted thiazolyl dihydropyrimidines
CA2693609A1 (en) 2007-07-12 2009-01-15 Novartis Ag Oral pharmaceutical solutions containing telbivudine
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PL2888241T3 (pl) 2012-08-24 2017-12-29 Sunshine Lake Pharma Co., Ltd. 2,4,5,6-Podstawione pochodne 3,6-dihydropirymidyny jako inhibitory polimerazy wirusa zapalenia wątroby typu B (HBV) do leczenia np. przewlekƂego zapalenia wątroby
BR112015004113A2 (pt) 2012-09-10 2017-07-04 Hoffmann La Roche 6-aminoåcido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
CN103664899B (zh) * 2012-09-11 2017-06-16 ćčżäžœäžœé˜łć…‰èŻäžšæœ‰é™ć…Źćž æ‚èŠłćŸșć–ä»Łçš„äșŒæ°ąć˜§ć•¶ç±»ćŒ–ćˆç‰©ćŠć…¶ćœšèŻç‰©äž­çš„ćș”甚
KR20150093685A (ko) * 2012-11-09 2015-08-18 읞디애나 유니ëČ„ì‹œí‹° ëŠŹì„œìč˜ ì•€ë“œ í…ŒíŹë†€ëĄœì§€ ìœ”íŹë ˆìŽì…˜ Hbv ì–Žì…ˆëž”ëŠŹ 읎펙터의 대ìČŽ 용도
TW201609652A (zh) * 2013-11-12 2016-03-16 陶氏èŸČæ„­ç§‘ć­žć…Źćž ç”šæ–Œæ°ŸćŒ–ćŒ–ćˆç‰©äč‹éŽçš‹ïŒˆäž‰ïŒ‰
MX2016006564A (es) 2013-11-19 2017-09-12 Sunshine Lake Pharma Co Ltd Compuestos dihidropirimidina y su aplicacion en productos farmaceuticos.
KR102284938B1 (ko) 2013-11-27 2021-08-02 선샀읞 ë ˆìŽíŹ 파넎마 컎퍌니 멬믾티드 ë‹€ìŽí•˜ìŽë“œëĄœí”ŒëŠŹëŻžë”˜ 유도ìČŽ 및 읎의 ì€‘ê°„ì‚°ëŹŒì˜ ì œìĄ° ë°©ëȕ
MX2016012573A (es) 2014-03-28 2018-02-19 Sunshine Lake Pharma Co Ltd Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.
CA2950807C (en) * 2014-05-30 2022-05-31 Medshine Discovery Inc. Dihydropyrimido fused ring derivative as hbv inhibitor
CN105153164B (zh) * 2014-05-30 2018-10-30 霐éČćˆ¶èŻæœ‰é™ć…Źćž 䜜äžșhbvæŠ‘ćˆ¶ć‰‚çš„äșŒæ°ąć˜§ć•¶ćč¶çŽŻèĄç”Ÿç‰©
TW201629054A (zh) 2015-02-07 2016-08-16 ć»Łæ±æ±é™œć…‰è—„æ„­æœ‰é™ć…Źćž äșŒæ°«ć˜§ć•¶èĄç”Ÿç‰©çš„è€‡ćˆç‰©ćŠć…¶ćœšè—„物䞭的應甚
EP3645516A4 (en) * 2017-06-27 2021-07-07 Janssen Pharmaceutica NV HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS
US10759774B2 (en) 2017-09-28 2020-09-01 The Curators Of The University Of Missouri Inhibitors of hepatitis B virus targeting capsid assembly
EA202091113A1 (ru) 2017-11-02 2020-08-28 АĐčĐșурос Đ“ĐŒĐ±Ń… ĐŁĐœĐŽ ĐšĐŸ. Кг ĐĐŸĐČыД ĐČŃ‹ŃĐŸĐșĐŸĐ°ĐșтоĐČĐœŃ‹Đ” Đ°ĐŒĐžĐœĐŸŃ‚ĐžĐ°Đ·ĐŸĐ»Đ·Đ°ĐŒĐ”Ń‰Đ”ĐœĐœŃ‹Đ” ĐžĐœĐŽĐŸĐ»-2-ĐșĐ°Ń€Đ±ĐŸĐșŃĐ°ĐŒĐžĐŽŃ‹, аĐșтоĐČĐœŃ‹Đ” ĐČ ĐŸŃ‚ĐœĐŸŃˆĐ”ĐœĐžĐž ĐČоруса гДпатОта b (hbv)
KR20200083552A (ko) 2017-11-02 2020-07-08 ì•„ìŽìż ëŠŹìŠ€ êČŒì— ëȠ하 욎튞 윔. ìčŽêȌ B형 ê°„ì—Œ ë°”ìŽëŸŹìŠ€ (hbv)에 활성읞 신규 êł í™œì„± í”ŒëŒìĄžëĄœ-í”ŒíŽ˜ëŠŹë”˜ ìč˜í™˜ëœ 읞돌-2-ìčŽë„Žëł”ìŠ€ì•„ëŻžë“œ
MA52586A (fr) * 2018-05-08 2021-03-17 Janssen Sciences Ireland Unlimited Co Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
JP2022506351A (ja) * 2018-11-02 2022-01-17 スむクăƒȘă‚č ă‚Čă‚Œăƒ«ă‚·ăƒŁăƒ•ăƒˆ ミット ăƒ™ă‚·ăƒ„ăƒŹăƒłă‚Żăƒ†ăƒ« ハフツング ォント ă‚łăƒłăƒ‘ăƒ‹ăƒŒ コマンディトă‚Čă‚Œăƒ«ă‚·ăƒŁăƒ•ăƒˆ ïŒąćž‹è‚ç‚Žă‚Šă‚€ăƒ«ă‚čïŒˆïœˆïœ‚ïœ–ïŒ‰ă«ćŻŸă—ăŠæŽ»æ€§ă‚’æœ‰ă™ă‚‹æ–°èŠă‚ŠăƒŹă‚ąïŒ–ïŒŒïŒ—ïŒă‚žăƒ’ăƒ‰ăƒ­ïŒïŒ”ïœˆïŒăƒă‚ąă‚Ÿăƒ­ïŒ»ïŒ•ïŒŒïŒ”ïŒïœƒïŒœăƒ”ăƒȘゾン
AR116946A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
UY38434A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
UY38435A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
UY38436A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
AR117188A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
US20220048919A1 (en) 2018-12-20 2022-02-17 Janssen Phrmaceutica NV Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
KR20220002499A (ko) 2019-04-30 2022-01-06 ì•„ìŽìż ëŠŹìŠ€ êČŒì— ëȠ하 욎튞 윔. ìčŽêȌ B형 ê°„ì—Œ ë°”ìŽëŸŹìŠ€ (hbv)에 대핮 활성읞 신규 페닐 및 í”ŒëŠŹë”œ 우레아
EP3962913A1 (en) 2019-04-30 2022-03-09 AiCuris GmbH & Co. KG Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
SG11202111493WA (en) 2019-04-30 2021-11-29 Aicuris Gmbh & Co Kg Novel oxalyl piperazines active against the hepatitis b virus (hbv)
US20220306647A1 (en) 2019-04-30 2022-09-29 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitus b virus (hbv)
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130304C (enExample) * 1964-02-12
CH550189A (de) 1971-01-08 1974-06-14 Ciba Geigy Ag Verfahren zur herstellung von neuen dibenzo (b,f) thiepincarbonsaeuren.
CH569043A5 (enExample) 1973-01-23 1975-11-14 Ciba Geigy Ag
US4371537A (en) * 1981-08-13 1983-02-01 The Dow Chemical Company Sulfur-substituted phenoxypyridines having antiviral activity
DE3234684A1 (de) * 1982-09-18 1984-03-22 Bayer Ag, 5090 Leverkusen Neue dihydropyrimidine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
JPS60185764A (ja) 1984-03-05 1985-09-21 Wako Pure Chem Ind Ltd ピăƒȘゾンèȘ˜ć°Žäœ“ăźæ–°èŠăȘèŁœé€ æł•
US4698340A (en) * 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
US4727073A (en) 1984-10-01 1988-02-23 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives and composition of the same
GB8906168D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
BR9713027A (pt) * 1996-11-12 2000-01-25 Novartis Ag Derivados de pirazol Ășteis como herbicidas
SE9702564D0 (sv) * 1997-07-02 1997-07-02 Astra Ab New compounds

Also Published As

Publication number Publication date
CU23049A3 (es) 2005-06-24
CZ293482B6 (cs) 2004-05-12
PE20000427A1 (es) 2000-06-25
IL138584A0 (en) 2001-10-31
GT199900056A (es) 2000-10-07
BG104812A (en) 2001-06-29
RU2245881C2 (ru) 2005-02-10
NO20005215D0 (no) 2000-10-17
BR9909730B1 (pt) 2012-09-04
MY126527A (en) 2006-10-31
ZA200005136B (en) 2001-03-02
PT1080086E (pt) 2002-12-31
CO5021127A1 (es) 2001-03-27
US7514565B2 (en) 2009-04-07
KR100636771B1 (ko) 2006-10-23
TR200003011T2 (tr) 2001-01-22
RU2245881C9 (ru) 2006-02-10
AU3813399A (en) 1999-11-08
PL343481A1 (en) 2001-08-27
BR9909730A (pt) 2000-12-19
ID27263A (id) 2001-03-22
CN1159311C (zh) 2004-07-28
JP5237332B2 (ja) 2013-07-17
AU740318B2 (en) 2001-11-01
DK1080086T3 (da) 2002-12-23
EP1080086B1 (de) 2002-09-04
US20070117812A1 (en) 2007-05-24
SK15652000A3 (sk) 2001-04-09
SV1999000047A (es) 2000-06-23
US20040167135A1 (en) 2004-08-26
ES2183548T3 (es) 2003-03-16
HUP0102372A3 (en) 2003-01-28
CA2328780A1 (en) 1999-10-28
PL193898B1 (pl) 2007-03-30
CA2328780C (en) 2008-09-23
EP1080086A1 (de) 2001-03-07
NO20045259L (no) 2000-12-13
JP2002512243A (ja) 2002-04-23
BG64649B1 (bg) 2005-10-31
HK1039119A1 (en) 2002-04-12
TW548274B (en) 2003-08-21
BRPI9917862B1 (pt) 2013-05-07
HUP0102372A2 (hu) 2001-12-28
IL138584A (en) 2006-09-05
WO1999054326A1 (de) 1999-10-28
ATE223401T1 (de) 2002-09-15
NO329020B1 (no) 2010-07-26
NZ507569A (en) 2002-04-26
JP4590097B2 (ja) 2010-12-01
SK286407B6 (sk) 2008-09-05
CN1305471A (zh) 2001-07-25
NO321985B1 (no) 2006-07-31
US6696451B1 (en) 2004-02-24
BRPI9917862A2 (enExample) 2010-12-07
NO20005215L (no) 2000-12-13
WO1999054326A8 (de) 1999-12-29
SI1080086T1 (en) 2003-02-28
JP2010241837A (ja) 2010-10-28
BRPI9917862B8 (pt) 2021-05-25
KR20010042788A (ko) 2001-05-25
CZ20003871A3 (cs) 2001-01-17
UA63998C2 (uk) 2004-02-16
DE59902573D1 (en) 2002-10-10
DE19817264A1 (de) 1999-10-21

Similar Documents

Publication Publication Date Title
AR018187A1 (es) Derivados de 1,4-dihidro-1,3-diazinas y 3,4-dihidro-1,3-diazinas, procedimiento para su preparacion, medicamentos, procedimiento para la produccion de los mismos y el uso de los mismos para la produccion de medicamentos
AR015765A1 (es) Dihidropirimidinas 2 heterociclicamente sustituidas, proceso para su preparacion, medicamentos que los contienen, proceso para la preparacion de los mismosuso de dichos dihidropirimidinas para la preparacion de un medicamento.
AR023308A1 (es) Uso de dihidropirimidinas para la preparacion de un medicamento, dihidropirimidinas, procedimiento para su produccion y preparados farmaceuticos que loscontienen.
AR063458A1 (es) Derivados de piridina inhibidores de 11beta hsd1
AR064130A1 (es) Derivados de tiazoles y piridinas como antibacterianos. composiciones farmaceuticas.
AR029805A1 (es) Compuestos heterociclicos, un proceso para su preparacion , intermediarios, composicion farmaceutica, un proceso para su preparacion, y el uso de dichos compuestos para la fabricacion de un medicamento
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
AR074596A1 (es) Derivados de (3-oxo) piridazin-4-ilurea
AR030279A1 (es) Derivados de fenilamida para-amino sustituida activadora de la glucoquinasa, un procedimiento para su preparacion, composiciones farmaceuticas y el empleo de dichos derivados para la preparacion de medicamentos.
AR035858A1 (es) Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
AR039648A1 (es) Compuestos de aril cetona pirrolo triazina utiles como inhibidores de cinasa y las composiciones farmaceuticas que las contienen
AR053232A1 (es) Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico.
AR033306A1 (es) Compuestos
AR059687A1 (es) Derivados de pirazol inhibidores de la enzima mao-b,utiles para mejorar la funcion cognitiva, composiciones farmaceuticas que los contienen,y metodo de preparacion.
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
CO4940477A1 (es) Inhibidores de proteasa
AR070274A1 (es) Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios.
AR044629A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
AR066873A1 (es) Derivados de triazolo (1,5-a) quinolina, procesos de obtencion y composiciones farmaceuticas
SE0101579D0 (sv) New compounds
AR002745A1 (es) 5,6-DIHIDRO-9H-PIRAZOL[3,4-c]-1,2,4-TRIAZOL [4,3-a] PIRIDINAS TRICICLICAS Y COMPOSICIONES FARMACEUTICAS CONTENIENDO LAS MISMAS.
AR008296A1 (es) Compuestos derivados de tetrahidroquinolina, proceso para su preparacion, composiciones que los contienen y su uso en la preparacion de una composicion
AR036074A1 (es) Derivados de aminoquinolina, las composiciones farmaceuticas que los contienen, el uso de los mismos para la preparacion de una composicion farmaceutica, un procedimiento para su preparacion y los intermediarios empleados en dicho procedimiento de preparacion
AR005233A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina, procesos para su preparacion, una composicion farmaceutica y el uso en la elaboracion de un medicamento

Legal Events

Date Code Title Description
FG Grant, registration